Skip to main content
SpringerLink
Log in

Drug-Induced Hepatic Disorders

Incidence, Management and Avoidance

  • Review Article
  • Pharmacoepidemiology
  • Published:
Drug Safety Aims and scope Submit manuscript

An Erratum to this article was published on 01 March 1994

Summary

Drug-induced liver injury has been associated with more than 800 different drugs, leading to hospital admission in 1 of 600 to 3500 admissions. This amounts to 2 to 3% of all hospitalisations due to adverse drug reactions, or about 3% of all jaundiced patients. The prognosis of clinically overt drug hepatotoxicity is relatively serious. The clinical picture is essentially nonspecific, with a highly variable latency period from days to years. Drug hepatotoxicity can mimic almost any kind of liver disease. A thorough drug history, a low threshold of suspicion and the exclusion of other causes of liver disease are important for the detection of drug-induced liver disorders.

Treatment consists of discontinuation of suspected drug(s), acetylcysteine in the course of paracetamol (acetaminophen) toxicity, and liver transplantation in selected cases of fulminant liver failure.

Guidelines regarding the use of selected drugs such as methotrexate and halothane should be followed. Potentially hepatotoxic drugs should be used cautiously in alcoholic patients with or without liver involvement. Patients with uncompensated liver disease should receive a reduced dose of drugs adjusted to the degree of liver function impairment.

The general public should be warned against abuse of hepatotoxic drugs such as paracetamol and anabolic steroids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Anonymous. Report of an international consensus meeting. Drug-induced liver disorders: standardization of definitions and criteria of causality assessment of adverse drug reactions. International Journal of Clinical Pharmacology, Therapy and Toxicology 28: 317–322.1990

    Google Scholar 

  • Bass NM, Williams RL. Guide to drug dosage in hepatic disease. Clinical Pharmacokinetics 15: 396–420, 1988

    Article  PubMed  CAS  Google Scholar 

  • Bernauau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Seminars in Liver Disease 6: 97–106, 1986

    Article  Google Scholar 

  • Biour M, Poupon R, Grange J-D, Chazoulleres O, Levy V-G, et al. Hepatotoxité des medicaments. Gastroenterologie Clinique et Biologique 16: 64–88, 1992

    PubMed  CAS  Google Scholar 

  • Bismuth H, Samuel D, Gugenheim J, Castaing D, Bernuau J, et al. Emergency liver transplantation for fulminant hepatitis. Annals of Internal Medicine 107: 337–341, 1987

    PubMed  CAS  Google Scholar 

  • Bjørneboe M, Iversen O, Olsen S. Infective hepatitis and toxic jaundice in municipal hospital during a five-year period. Acta Medica Scandinavica 182: 491–501, 1967

    Article  PubMed  Google Scholar 

  • Boekhorst T, Urlus M, Doesburg W, Yap SH, Gorris RJA. Etiologic factors of jaundice in severely ill patients. Journal of Hepatology 7: 111–117, 1988

    Article  Google Scholar 

  • Bonacini M. Hepatobiliary complications in patients with human immunodeficiency virus infection. American Journal of Medicine 92: 404–411, 1992

    Article  PubMed  CAS  Google Scholar 

  • Bottiger LE, Furhoff AK, Holmberg L. Fatal reactions to drugs. Acta Medica Scandinavica 205: 451–456, 1979

    Article  PubMed  CAS  Google Scholar 

  • Boston Collaborative Drug Surveillance Program. Archives of Internal Medicine 134: 219–233, 1974

    Article  Google Scholar 

  • Bray GP, Mowt C, Muir DF, Tredgar JM, Williams R. The effect of chronic alcohol intake on the prognosis and outcome in paracetamol overdose. Human and Experimental Toxicology 10: 435–438.1991

    Article  PubMed  CAS  Google Scholar 

  • Crombie DL. Monitoring adverse drug reactions. Journal of the Royal College of General Practitioners 25: 337–343, 1975

    PubMed  CAS  Google Scholar 

  • Denison H, Kaczynnski J, Wallerstedt S. Paracetamol medication and alcohol abuse: a dangerous combination for the liver and kidney. Scandinavian Journal of Gastroenterology 22: 701–704, 1987

    Article  PubMed  CAS  Google Scholar 

  • Døssing M, Andereasen PB. Drug-induced liver disease in Denmark. Scandinavian Journal of Gastroenterology 17: 205–211, 1982

    Article  PubMed  Google Scholar 

  • Døssing M, Andreasen PB, Ranek L, Johansen SH. Possibilities of prevention of halothane hepatitis. Ugeskrift for Laeger 144: 466–468, 1982

    PubMed  Google Scholar 

  • Ellard GA, Mitchison DA, Girling DJ, Nunn AJ, Fox W. The hepatic toxicity of isoniazid among rapid and slow acetylators of the drug. American Review of Respiratory Disease 118: 628–629, 1978

    PubMed  CAS  Google Scholar 

  • Farrel G, Prendergast D, Murrey M. Halothane hepatitis. New England Journal of Medicine 313: 1310–1314, 1985

    Article  Google Scholar 

  • Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to The Danish Committee on Adverse Drug Reactions between 1978 and 1987. Journal of Internal Medicine 232: 133–138, 1992

    Article  PubMed  CAS  Google Scholar 

  • Geubel A, Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology 100: 1701–1709, 1991

    PubMed  CAS  Google Scholar 

  • Gram L, Bentsen HD. Hepatic toxicity of antiepileptic drug: a review. Acta Neurologica Scandinavica 68(Suppl. 97): 81–90, 1983

    Article  Google Scholar 

  • Gronhagen-Riska C, Hellstrom P-E, Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampicin treatment of tuberculosis. American Review of Respiratory Disease 118: 461–466, 1978

    PubMed  CAS  Google Scholar 

  • Hallas H, Gram LF, Grodum E, Damsbo N, Brøsen N, et al. Drug related admissions to medical wards: a population based survey. British Journal of Clinical Pharmacology 33: 61–68, 1992

    Article  PubMed  CAS  Google Scholar 

  • Ishah G, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Seminars in Liver Disease 7: 230–236, 1987

    Article  Google Scholar 

  • Jick H. Drugs — remarkably nontoxic. New England Journal of Medicine 291: 824–828, 1974

    Article  PubMed  CAS  Google Scholar 

  • Jick H, Walker AM, Porter J. Drug-induced liver disease. Journal of Clinical Pharmacology 21: 359–364, 1981

    PubMed  CAS  Google Scholar 

  • Koff RS, Gardner RC, Harinasuta U, Pihl CO. Profile of hyperbilirubinemia in three hospital populations. Clinical Research 79: 524, 1971

    Google Scholar 

  • Kopanoff DE, Snider DE, Caras G. Isoniazid-related hepatitis. American Review of Respiratory Medicine 117: 991–1001, 1978

    CAS  Google Scholar 

  • Larrey D, Benson A, Habersetzer F, Tinel M, Castot A, et al. Genetic predisposition to drug hepatotoxicity: role in hepatitis caused by amineptine, a tricyclic antidepressant. Hepatology 10: 166–173, 1989

    Article  Google Scholar 

  • Larrey D, Erlinger S. Drug-induced cholestasis. Bailliere’s Clinical Gastroenterology 2: 423–452, 1988

    Article  PubMed  CAS  Google Scholar 

  • Larrey D, Vial T, Pauwells A, Castot A, Biour M, et al. Hepatitis after germander (teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Annals of Internal Medicine 117: 129–132, 1992

    PubMed  CAS  Google Scholar 

  • Lewis JH, Renard RC, Caruso A, Jackson LK, Mullick F, et al. Amiodarone hepatotoxicity: the prevalence and clinicopathologic correlations among 104 patients. Hepatology 9: 679–685, 1989

    Article  PubMed  CAS  Google Scholar 

  • Lewis JH, Schiff ER, Methotrexate-induced chronic liver injury: guidelines for detection and prevention. American Journal of Gastroenterology 83: 1377–1345, 1988

    Google Scholar 

  • Lewis JH, Zimmerman HJ. Drug-induced liver disease. Medical Clinics of North America 73: 775–792, 1989

    PubMed  CAS  Google Scholar 

  • Lieber C. Metabolic effects of ethanol and its interaction with other drugs, hepatotoxic agents, vitamins and carcinogens: a 1988 update. Seminars in Liver Disease 8: 47–68, 1988

    Article  PubMed  CAS  Google Scholar 

  • Mitchell JR, Thorgiersson VP, Black M, Timbrell JA, Snodgrass WS. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clinical Pharmacology and Therapeutics 18: 70–79, 1975

    PubMed  CAS  Google Scholar 

  • Morgan MY, Reshef R, Shah RR, Oates NS, Smith RH, et al. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 25: 1057–1064, 1984

    Article  PubMed  CAS  Google Scholar 

  • Morrison AS, Jick H, Ory HW. Oral contraceptives and hepatitis. Lancet 1: 1142–1143, 1977

    Article  PubMed  CAS  Google Scholar 

  • Moulding TS, Redeker AG, Kanel GC. Acetaminophen, isoniazid, and hepatic toxicity. Annals of Internal Medicine 114: 431, 1991

    PubMed  CAS  Google Scholar 

  • Murphy R, Schwartz R, Watkins PB. Severe acetaminophen toxicity in a patient receiving isoniazid. Annals of Internal Medicine 113: 791–800, 1990

    Google Scholar 

  • Naranjo CA, Busto U, Janecek E, Ruiz I, Roach CA, et al. An intensive drug monitoring study suggesting possible clinical irrelevance of impaired drug disposition in liver disease. British Journal of Clinical Pharmacology 15: 451–458, 1983

    Article  PubMed  CAS  Google Scholar 

  • Neuberger JM. Halothane and hepatitis. Drug Safety 5: 28–38, 1990

    Article  PubMed  CAS  Google Scholar 

  • Pessayre D, Bentata M, Degott C, Nouel O, Miguet J-P, et al. Isoniazid-rifampicin fulminant hepatitis. Gastroenterology 72: 284–289, 1977

    PubMed  CAS  Google Scholar 

  • Ranek L, Andreasen PB. Disulfiram hepatotoxicity. British Medical Journal 1: 94–96, 1977

    Article  Google Scholar 

  • Rigas B. The evolving spectrum of amiodarone hepatotoxicity. Hepatology 10: 116–117, 1989

    Article  PubMed  CAS  Google Scholar 

  • Shulman HM, Sharma P, Deborah A, Fenster F, McDonald G. A coded histologic study of graft-versus-host disease after human bone marrow transplantation. Hepatology 8: 463–470, 1988

    Article  PubMed  CAS  Google Scholar 

  • Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB. Acetaminophen hepatotoxicity in alcoholics: a therapeutic misadventure. Annals of Internal Medicine 104: 399–404, 1986

    PubMed  CAS  Google Scholar 

  • Shah KA, Levin J, Rosen N, Greenvald E, Zumoff B. Allopurinol hepatotoxicity potentiated by tamoxifen. New York State Journal of Medicine 82: 1745–1746, 1982

    PubMed  CAS  Google Scholar 

  • Sherlock S. Patterns of hepatocyte injury in man. Lancet 1: 782–786, 1982

    Article  PubMed  CAS  Google Scholar 

  • Shriner KY, Goetz MB. Severe hepatotoxicity in a patient receiving both acetaminophen and zidovudine. American Journal of Medicine 93: 94–96, 1992

    Article  PubMed  CAS  Google Scholar 

  • Sonne J, Andreasen PB, Loft S, Døssing M. Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. Hepatology 11: 951–956, 1990

    Article  PubMed  CAS  Google Scholar 

  • Soumerai SB, Ross-Degnan P, Kahn JS. Effects of professional and media warnings about association between aspirin use in children and Reye’s syndrome. Milbank Quarterly 70: 155–182, 1992

    Article  PubMed  CAS  Google Scholar 

  • Spielberg SP, Gordon GB, Blake DA, Goldstein D, Herlong A. Predisposition to phenytoin hepatotoxicity assessed in vitro. New England Journal of Medicine 305: 722–727, 1981

    Article  PubMed  CAS  Google Scholar 

  • Steele MA, Burk RF, DesPreez RM. Toxic hepatitis with isoniazid and rifampicin: a meta-analysis. Chest 99: 465–471, 1991

    Article  PubMed  CAS  Google Scholar 

  • Tiller J, Treasure J. Purging with paracetamol: report of four cases. British Medical Journal 305: 618, 1992

    Article  PubMed  CAS  Google Scholar 

  • Wu J-C, Lee S-D, Yeh P-F, Chan C-Y, Wang Y-J, et al. Isoniazid-rifampicin induced hepatitis in hepatitis B carriers. Gastroenterology 98, 502–504, 1990

    PubMed  CAS  Google Scholar 

  • Waller PC. Measuring the frequency of adverse drug reactions. British Journal of Clinical Pharmacology 33: 249–252, 1992

    Article  PubMed  CAS  Google Scholar 

  • Wyllie E, Wyllie R. Routine laboratory monitoring of serious adverse effects of antiepileptic medications: the controversy. Epilepsia 32(Suppl. 5): 75–79, 1991

    Google Scholar 

  • Zimmerman H. Drug-induced liver disease. Drugs 16: 25–46, 1978

    Article  PubMed  CAS  Google Scholar 

  • Zimmerman H. Drug-induced chronic hepatic disease. Medical Clinics of North America 63: 567–582, 1979

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Department P, Bispebjerg Hospital, Bispebjerg Bakke 23, DK-2400, Copenhagen NV, Denmark

    Martin Døssing

  2. Medical Department F, Gentofte Hospital, Hellerup, Denmark

    Jesper Sonne

Authors
  1. Martin Døssing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jesper Sonne
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF03258532.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Døssing, M., Sonne, J. Drug-Induced Hepatic Disorders. Drug-Safety 9, 441–449 (1993). https://doi.org/10.2165/00002018-199309060-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199309060-00007

Keywords

Search

Navigation